- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 8, 2019
Company News
Why dwarfism start-up Therachon picked Pfizer takeout over IPO
At the cusp of seeking a public listing, Therachon Holding chose $340M deal with Pfizer and the chance to spin out a new company
BioCentury | Apr 6, 2017
Targets & Mechanisms
Competing for growth
Therachon and BioClin hope FGFR3 blockers can outlast BioMarin’s vosoritide
Items per page:
1 - 10 of 30